Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer

Research output: Contribution to journalArticle

  • External authors:
  • Malcolm Ranson
  • Emma Dean
  • Duncan Jodrell
  • Kate Connolly
  • Sarah Danson
  • Jacques Jolivet
  • Jon Durkin
  • Stephen Morris
  • Debra Jowle
  • Tim Ward
  • Jeff Cummings
  • Gemma Dickinson
  • Eric LaCasse
  • Lesley Robson
  • Caroline Dive


Purpose To establish the maximum-tolerated dose and evaluate tolerability, pharmacokinetics, pharmacodynamic effects, and antitumor activity of AEG35156, a second-generation antisense to X-linked inhibitor of apoptosis(XIAP) protein, in patients with advanced refractory malignant tumors. Patients and Methods This was a first-in-man, open-label, phase I dose-escalation study. AEG35156 was administered by continuous intravenous infusion over 7 days(7DI) or 3 days(3DI) of a 21-day treatment cycle. Dose escalation started at 48 mg/m2/d and continued until consistent dose-limiting toxicity(DLT) was observed. Results Thirty-eight patients were entered in seven cohorts. Grade 3 to 4 adverse events were uncommon and were predominantly abnormal laboratory values: elevated ALT, thrombocytopenia, and lymphopenia. DLTs comprised elevated hepatic enzymes, hypophosphatemia, and thrombocytopenia. The maximum-tolerated doses were defined as 125 mg/m2/d for the 7DI regimen and ≤ 213 mg/m2/d for the 3DI schedule. AEG35156 area under the plasma concentration curve and peak plasma concentration increased proportionally with dose. Suppression of XIAP mRNA levels was maximal at 72 hours(mean suppression, 21%), and this coincided with a dramatic decrease in circulating tumor cells in a patient with non-Hodgkin's lymphoma. Two further patients had unconfirmed partial responses. Circulating biomarkers of cell death and apoptosis altered in association with drug infusion and toxicity. Conclusion In this first-in-man study, AEG35156 was well tolerated, with predictable toxicities, pharmacokinetic properties, and clinical evidence of antitumor activity in patients with refractory lymphoma, melanoma, and breast cancer. Phase I/II trials of AEG35156 chemotherapy combinations are ongoing in patients with pancreatic, breast, non-small-cell lung cancer, acute myeloid leukemia, lymphoma, and solid tumors for which docetaxel is indicated. © 2009 by American Society of Clinical Oncology.

Bibliographical metadata

Original languageEnglish
Pages (from-to)1660-1666
Number of pages6
JournalJournal of Clinical Oncology
Issue number10
Publication statusPublished - 1 Apr 2009